Have a feature idea you'd love to see implemented?
Let us know!
ALNY Alnylam Pharmaceuticals Inc
Price (delayed)
$243.75
Market cap
$31.44B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.61
Enterprise value
$31.64B
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is
Highlights
The equity has soared by 120% YoY
ALNY's EPS is up by 36% year-on-year
The gross profit is up by 24% YoY but it is down by 12% from the previous quarter
The company's revenue rose by 22% YoY but it fell by 11% QoQ
The company's quick ratio fell by 11% YoY and by 8% QoQ
Key stats
What are the main financial stats of ALNY
Market
Valuations
Earnings
Shares outstanding
128.98M
Market cap
$31.44B
Enterprise value
$31.64B
Price to earnings (P/E)
N/A
Price to book (P/B)
967.2
Price to sales (P/S)
14.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.1
Revenue
$2.09B
Gross profit
$1.79B
Net income
-$332.26M
EBIT
-$186.88M
EBITDA
-$85.69M
Free cash flow
$16.06M
Per share
Balance sheet
Liquidity
EPS
-$2.61
EPS diluted
-$2.61
Free cash flow per share
$0.12
Book value per share
$0.25
Revenue per share
$16.29
TBVPS
$32.7
Total assets
$4.21B
Total liabilities
$4.17B
Debt
$1.3B
Equity
$32.35M
Working capital
$2.13B
Debt to equity
40.24
Current ratio
2.75
Quick ratio
2.57
Net debt/EBITDA
-2.36
Margins
Efficiency
Dividend
EBITDA margin
-4.1%
Gross margin
85.4%
Net margin
-15.9%
Operating margin
-9%
Return on assets
-8.4%
Return on equity
N/A
Return on invested capital
-5.6%
Return on capital employed
-6.3%
Return on sales
-8.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALNY stock price
How has the Alnylam Pharmaceuticals stock price performed over time
Intraday
0.21%
1 week
2.04%
1 month
-3.79%
1 year
27.48%
YTD
27.34%
QTD
-11.37%
Financial performance
How have Alnylam Pharmaceuticals's revenue and profit performed over time
Revenue
$2.09B
Gross profit
$1.79B
Operating income
-$188.13M
Net income
-$332.26M
Gross margin
85.4%
Net margin
-15.9%
The company's operating margin has surged by 56% YoY
Alnylam Pharmaceuticals's operating income has increased by 47% YoY
The net margin has grown by 46% YoY
The company's net income rose by 35% YoY
Growth
What is Alnylam Pharmaceuticals's growth rate over time
Valuation
What is Alnylam Pharmaceuticals stock price valuation
P/E
N/A
P/B
967.2
P/S
14.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.1
ALNY's EPS is up by 36% year-on-year
The equity has soared by 120% YoY
ALNY's price to sales (P/S) is 44% lower than its 5-year quarterly average of 26.8 but 14% higher than its last 4 quarters average of 13.1
The company's revenue rose by 22% YoY but it fell by 11% QoQ
Efficiency
How efficient is Alnylam Pharmaceuticals business performance
ALNY's return on sales has surged by 60% year-on-year
ALNY's return on invested capital has surged by 53% year-on-year
The return on assets has increased by 42% year-on-year
Dividends
What is ALNY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALNY.
Financial health
How did Alnylam Pharmaceuticals financials performed over time
Alnylam Pharmaceuticals's current ratio has decreased by 12% YoY and by 9% from the previous quarter
The company's quick ratio fell by 11% YoY and by 8% QoQ
The equity has soared by 120% YoY
Alnylam Pharmaceuticals's debt to equity has soared by 109% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.